RIMCURE 150/75/400 Milligram Film Coated Tablet Irland - engelska - HPRA (Health Products Regulatory Authority)

rimcure 150/75/400 milligram film coated tablet

sandoz gmbh - rifampicin isoniazid pyrazinamide - film coated tablet - 150/75/400 milligram

RIMSTAR Film Coated Tablet 150/75/400 Milligram Irland - engelska - HPRA (Health Products Regulatory Authority)

rimstar film coated tablet 150/75/400 milligram

sandoz gmbh - rifampicin isoniazid pyrazinamide ethambutol dihydrochloride - film coated tablet - 150/75/400 milligram

KLARAM 250 Milligram Film Coated Tablet Irland - engelska - HPRA (Health Products Regulatory Authority)

klaram 250 milligram film coated tablet

actavis group ptc ehf - clarithromycin - film coated tablet - 250 milligram

KLARAM 500 Milligram Film Coated Tablet Irland - engelska - HPRA (Health Products Regulatory Authority)

klaram 500 milligram film coated tablet

actavis group ptc ehf - clarithromycin - film coated tablet - 500 milligram

RIMSTAR 150/75/400 Milligram Film Coated Tablet Irland - engelska - HPRA (Health Products Regulatory Authority)

rimstar 150/75/400 milligram film coated tablet

sandoz gmbh - rifampicin isoniazid pyrazinamide ethambutol dihydrochloride - film coated tablet - 150/75/400 milligram

ALPHAPRESS 50 hydralazine hydrochloride 50 mg tablet bottle Australien - engelska - Department of Health (Therapeutic Goods Administration)

alphapress 50 hydralazine hydrochloride 50 mg tablet bottle

alphapharm pty ltd - hydralazine hydrochloride, quantity: 50 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium starch glycollate; colloidal anhydrous silica; purified talc; disodium edetate; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; indigo carmine; sunset yellow fcf; iron oxide yellow; macrogol 4000; erythrosine - this product accepted for registration as 'currently supplied' at the time of commencement of the act. amended product information (variation to pregnancy statement) was approved as specified in the letter of 13 august 92 from dr bijoy varma. indications as at 28 november 2001 : hypertension (drug resistant, moderate to severe): as supplementary medication for use together with other antihypertensives such as "beta"-blockers and diuretics; the complementary mechanisms of action of such combined therapy enable the drugs to exert their antihypertensive effects at low doses; in addition, unwanted accompanying effects of the individual substances are either partially offset or even cancelled out.